From Wednesday, February 1, Australians have subsidized access to new drugs for ovarian and lung cancer which will reduce the price they pay by nearly 100%.
These drugs, which would otherwise cost more than A$100,000 ($76,000), will now set Australians back just A$6.30 for concessional patients and A$38.80 for others.
"Without subsidy, these medicines would be unaffordable for most Australians"
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze